May 24, 2023 | Endpoints News
Endpoints News Names Alexandra Collin de l’Hortet, Ph.D. in Their Report "The 20 Biotech Leaders Under the Age of 40"
The 20(+2) under 40: Your guide to the next generation of biotech leaders
March 16, 2023 | Scrip
‘Epigenetic Engineering’ Gene Therapy From Epic Bio Shows Early Promise
The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.
January 4, 2023 | BioSpace
Top Life Sciences Startups to Watch in 2023
Epic Bio honored in NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
December 7, 2022 | Endpoints News
Endpoints News Names Amber Salzman, Ph.D., in Their report "20 of The Top Women Leading Biopharma R&D 22"
Special report 2022: Meet 20 women blazing trails in biopharma R&D
August 26, 2022 | Labiotech
Epic Bio makes gene therapies by editing the epigenome
To overcome the obstacles for CRISPR-Cas9 gene editing, the startup Epic Bio was launched in July 2022 with an impressive Series A round worth $55 million.
July 26, 2022 | GEN
This is Epic: Epigenomic CRISPR Startup Goes Big by Thinking Small
Epic Bio, founded by Stanford bioengineer Stanley Qi, builds pipeline with tiniest Cas protein, epigenetic modulators, a platform that combines them, and proceeds from $55M Series A.
July 26, 2022 | BioPharma Dive
Epigenetic editing: a tunable CRISPR alternative
The startup is funded by Horizons Ventures and led by Amber Salzman, who has headed multiple genetic medicine companies, most recently Adverum Biotechnologies.
July 15, 2022 | BioWorld
CRISPR co-inventor’s Epic Bio launches with $55M series A
Controlling the epigenetics of a patient, figuring out what genes are expressed and understanding their level of expression, is at the center of Epic Bio, a new company founded by Stanley Qi.
July 13, 2022 | BioCentury
Epic Bio: Epigenome editing via compact components
Epic Bio is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.
July 12, 2022 | San Francisco Business Times
Why Hong Kong's richest person is betting on a Peninsula biotech startup
By not cutting out the bad part of a gene before replacing it with a correct DNA sequence — the essence of the CRISPR editing technology — the South San Francisco company believes its platform can reduce potential errors and side effects to fix a range of genetic diseases.
July 12, 2022 | Endpoints News
Big Pharma vet teams with former Doudna pupil to launch new epigenome startup
A former doctoral candidate in CRISPR pioneer Jennifer Doudna’s lab founded a new biotech seeking to wade into “epigenetics-level gene editing,” and has now secured enough capital to do just that.
July 12, 2022 | FierceBiotech
An Epic in miniature: CRISPR pioneer's startup reels in $55M to use tiny Cas for epigenetic engineering
CRISPR co-inventor Stanley Qi, Ph.D., is out with a new biotech that wants to make a big splash by going small.
Load More Stories